From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
LAG-3 biner 1 (compound 3) is a small molecule ligand (Kd=1.23 μM) for the immune checkpoint lymphocyte activation gene 3(LAG-3).LAG-3 biner 1 can be used in the research of cancer diagnosis targeting LAG-3 .
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) [3].
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
Lag3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lag3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
LAG3 Human Pre-designed siRNA Set A contains three designed siRNAs for LAG3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Lag3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lag3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity [3].
SA-15-P inhibits LAG-3/MHCII and LAG-3/FGL1 interactions with IC50 values of 4.21 and 6.52 μM respectively. LAG-3/MHCII interaction is a target for immunotherapies .
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50 of 0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3+CD8 + Infiltration of T cells and LAG3+CD8 + T cells was reduced .
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) [3].
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity [3].
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (HEK293, Fc) is the recombinant human-derived LAG-3 protein, expressed by HEK293 , with C-hFc labeled tag.
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (HEK293, His) is the recombinant human-derived LAG-3 protein, expressed by HEK293 , with C-6*His labeled tag.
LAG-3 Protein, expressed on antigen-activated T-cells, delivers inhibitory signals by binding to ligands like FGL1. LAG-3 Protein associates with CD3-TCR, directly inhibiting T-cell activation. LAG-3 Protein, Cynomolgus (428a.a, HEK293, His) is a recombinant protein dimer complex containing cynomolgus-derived LAG-3 protein, expressed by HEK293 , with N-8*His labeled tag. LAG-3 Protein, Cynomolgus (428a.a, HEK293, His), has molecular weight of 55-65 kDa.
LAG-3 (lymphocyte activation gene 3) protein is expressed on antigen-activated T cells and transmits inhibitory signals by binding to ligands such as FGL1. FGL1 is the main ligand responsible for the suppressive function of LAG3 T cells. LAG-3 Protein, Marmoset (HEK293, His) is the recombinant Marmoset-derived LAG-3 protein, expressed by HEK293 , with C-10*His labeled tag.
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (HEK293, mFc) is the recombinant human-derived LAG-3 protein, expressed by HEK293 , with C-mFc labeled tag.
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (HEK293, Llama Fc) is the recombinant human-derived LAG-3 protein, expressed by HEK293, with C-Llama Fc labeled tag.
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (Biotinylated, HEK293, mFc-Avi) is the recombinant human-derived LAG-3 protein, expressed by HEK293 , with C-Avi, C-mFc labeled tag.
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived LAG-3 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.
LAG-3 Protein, expressed on antigen-activated T-cells, delivers inhibitory signals by binding to ligands like FGL1. LAG-3 Protein associates with CD3-TCR, directly inhibiting T-cell activation. LAG-3 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived LAG-3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of LAG-3 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is 432 a.a., with molecular weight of 60-80 kDa.
LAG-3 (lymphocyte activation gene 3) protein is expressed on antigen-activated T cells and transmits inhibitory signals by binding to ligands such as FGL1.FGL1 is the main ligand responsible for the suppressive function of LAG3 T cells.LAG-3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived LAG-3 protein, expressed by HEK293 , with C-His labeled tag.
LAG-3 (lymphocyte activation gene 3) protein is expressed on antigen-activated T cells and transmits inhibitory signals by binding to ligands such as FGL1.FGL1 is the main ligand responsible for the suppressive function of LAG3 T cells.LAG-3 Protein, Mouse (HEK293) is the recombinant mouse-derived LAG-3 protein, expressed by HEK293 , with tag free.
LAG-3 (lymphocyte activation gene 3) protein is expressed on antigen-activated T cells and transmits inhibitory signals by binding to ligands such as FGL1.FGL1 is the main ligand responsible for the suppressive function of LAG3 T cells.LAG-3 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived LAG-3 protein, expressed by HEK293 , with C-hFc labeled tag.
LAG-3 (lymphocyte activation gene 3) protein is an inhibitory receptor on antigen-activated T cells, which transmits inhibitory signals by binding to ligands such as FGL1. LAG-3 is associated with CD3-TCR at the immune synapse, hinders T cell activation, and may cooperate with PDCD1/PD-1 to act as a co-receptor for PD-1. LAG-3 Protein, Rat (HEK293, His) is the recombinant rat-derived LAG-3 protein, expressed by HEK293 , with C-His labeled tag.
LAG-3 (lymphocyte activating gene 3) protein is an inhibitory receptor on antigen-activated T cells and is critical for immune regulation. LAG-3 binds to FGL1 and transmits inhibitory signals that negatively affect CD8(+) and CD4(+) T cell proliferation, activation, and effector functions. LAG-3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LAG-3 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
LAG-3 (lymphocyte activation gene 3) protein is expressed on antigen-activated T cells and transmits inhibitory signals by binding to ligands such as FGL1. FGL1 is the main ligand responsible for the suppressive function of LAG3 T cells. LAG-3 Protein, Canine (HEK293, Flag, His) is the recombinant canine-derived LAG-3 protein, expressed by HEK293 , with C-His, C-Flag labeled tag.
FGL1 protein is the main ligand of LAG3 and can inhibit antigen-specific T cell activation, mediating the inhibitory function of LAG3 independently of MHC-II binding. FGL1 is secreted by liver cells and contributes to their growth.FGL1 protein, Human (HEK293, 242a.a, His-Avi) is the recombinant human-derived FGL1 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.
FGL1 protein is the main ligand of LAG3 and can inhibit antigen-specific T cell activation, mediating the inhibitory function of LAG3 independently of MHC-II binding. FGL1 is secreted by liver cells and contributes to their growth. FGL1 Protein, Human (Biotinylated, 242a.a, HEK293, hFc) is the recombinant human-derived FGL1 protein, expressed by HEK293 , with N-hFc labeled tag.
FGL1 protein is the main ligand of LAG3 and can inhibit antigen-specific T cell activation, mediating the inhibitory function of LAG3 independently of MHC-II binding. FGL1 is secreted by liver cells and contributes to their growth. FGL1 Protein, Human (Biotinylated, 242a.a, HEK293, His-Avi) is the recombinant human-derived FGL1 protein, expressed by HEK293 , with N-Avi, N-His labeled tag.
LAG3 Antibody (YA1461) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1461), targeting LAG3. LAG3 Antibody (YA1461) can be used for FC, ELISA experiment in human background.
CD223/LAG-3 Antibody (YA4668) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD223/LAG-3. It can be applicated for ELISA assays, in the background of human.
CD223 Antibody (YA3842) is a mouse-derived and non-conjugated IgG1 antibody, targeting to CD223. It can be applicated for WB, FC, ELISA assays, in the background of human.
Lag3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lag3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
LAG3 Human Pre-designed siRNA Set A contains three designed siRNAs for LAG3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Lag3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lag3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
